Preparation method and application of pomalidomide derivatives as feed additives
By introducing ether chain structures on pomalidomide molecules and connecting them with urea compounds, a pomalidomide derivative was designed to inhibit urease activity, which solved the insufficient application of pomalidomide in melanoma treatment. The problem is to achieve effective inhibition of urease and adaptability to industrial production.
Patent Information
- Application Number
- CN202211301550.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-10-24
AI Technical Summary
The existing pomalidomide is less used in melanoma treatment and lacks effective feed additives to inhibit urease activity, affecting its application in tumor treatment.
By introducing an ether chain structure to the molecular structure of pomalidomide and connecting it with urea compounds, a pomalidomide derivative was designed, using it as an IDO1 inhibitor to inhibit urease activity through protein degradation, and developed A simple and efficient method for producing nitrobenzene from iodine benzene, suitable for large-scale industrial production.
Effective inhibition of urease is achieved, the degradation activity of IDO1 enzyme is improved, the inhibitory effect on melanoma is significantly improved, and it is suitable for industrial production, with low toxicity and high efficiency.
Smart Images

Figure CN115557936B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of synthesis of feed additives, and in particular relates to a preparation method and application of a pomalidomide derivative which can be used as a feed additive. Background Art
[0002] Immunomodulatory drugs (IMiD) can increase the production of IL-2 by T lymphocytes and reduce the production of pro-inflammatory cytokines. These effects make it widely used in the clinical treatment of diseases such as tumors. Pomalidomide is a third-generation immunomodulatory drug (IMiD) developed by Celgene Corporation in the United States. Its chemical name is 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione. It is a modified and synthesized drug based on the chemical structure of the first-generation IMiD thalidomide. It can enhance the immune response mediated by T cells and natural killer cells, inhibit the production of pro-inflammatory cytokines in monocytes, and induce tumor cell apoptosis. It has received widespread attention in the treatment of various malignant tumors and immune diseases. Compared with the first and second generation IMiDs, pomalidomide has stronger pharmacology, less toxicity and better patient tolerance. Its good anti-angiogenesis, anti-tumor and anti-inflammatory effects have been widely recognized in the early clinical studies of multiple myeloma (MM). Currently, there are few reports on the treatment of melanoma with pomalidomide. We hope to modify the molecular structure of pomalidomide to make it have an inhibitory effect on melanoma.
[0003]
[0004] Urea structural fragments are important advantageous skeletons in medicinal chemistry. Compounds containing urea structures usually have multiple biological activities and have become one of the most commonly used advantageous fragments in drug design. Structurally, urea consists of two amino groups connected by an intermediate carbonyl group. The carbonyl group can act as a hydrogen bond acceptor to accept two hydrogen bonds, and the proton on the N atom can act as a hydrogen bond donor to provide 2-4 hydrogen bonds (depending on the different substituents of the N atom). Urea has a super strong hydrogen bond forming ability and can form intermolecular hydrogen bonds through the NH of one molecule and the carbonyl oxygen atom of another molecule, thereby constructing chains, belts, α or β layers, etc. to form organized structures. Therefore, the introduction of urea structural fragments in drug molecule design and optimization can improve activity, increase selectivity, regulate physical and chemical properties, help overcome metabolic stability, remove toxic pharmacophores, etc. Our company has designed an IDO1 inhibitor with a urea structure, which can improve the body's immunity and inhibit the activity of urease, and can be used as a feed additive to improve immunity.
[0005] The molecular structure of pomalidomide is currently frequently used as a ligand to connect to E3 ligase in PROTAC molecules. It plays a vital role in the development of protease degradation drugs, which is currently very popular. Therefore, based on the design method of PROTAC molecules, we first introduced an ether chain structure into the pomalidomide structure, and then connected urea compounds with different substituents to the other end of the ether chain. We hope that this compound molecule can inhibit the activity of urease by protein degradation and can be used as a feed additive. Summary of the invention
[0006] The technical problem solved by the invention is to provide a preparation method and application of a pomalidomide derivative which can be used as a feed additive.
[0007] The present invention adopts the following technical solution to solve the above technical problems, a method for preparing a pomalidomide derivative, characterized by the specific steps of:
[0008] 1. Add a certain amount of methyl benzoate and calcium carbonate to a dichloroethane solution, stir, and then slowly drop a dichloroethane solution containing iodine chloride. After the addition is complete, heat to reflux and stir for a period of time, then cool and filter the reaction solution, then add anhydrous magnesium sulfate, stir and filter, add a certain amount of 3-aminopiperidine-2,6-dione hydrochloride, triethylamine and N,N'-dicyclohexylcarboximide to the filtrate, stir the reaction at room temperature for a period of time, then concentrate, then wash the concentrate with ether for several times, and then add the concentrate to toluene , then add triphenylphosphine and iodine, heat to reflux, remove water in the reaction system through a water separator, and then add a certain amount of palladium acetate and triethylamine. After stirring for a period of time under nitrogen protection, add anhydrous formic acid, maintain a nitrogen atmosphere, adjust the temperature of the reaction system to 80°C, stop the reaction after the reaction is completed, filter the reaction solution while hot, add water, stir, extract with dichloromethane for several times, combine the organic phases, and concentrate to obtain 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione.
[0009] 2. Add a certain amount of methyl benzoate and calcium carbonate to a dichloroethane solution, stir, and then slowly drop a certain amount of dichloroethane solution containing a certain amount of iodine chloride. After the addition is complete, heat to reflux and stir for a period of time, then cool and filter the reaction solution, then add anhydrous magnesium sulfate, stir and filter, add a certain amount of 3-aminopiperidine-2,6-dione hydrochloride, triethylamine and N,N'-dicyclohexylcarboximide to the filtrate, stir the reaction at room temperature for a period of time, then concentrate, and then wash the concentrate with ether for several times, then add the concentrate to glycerol, place it in a high-pressure reactor, and then add a certain amount of triphenylmethane Phosphine palladium chloride, acetylacetonate molybdenum and alkaline substances are stirred evenly and then the air in the reactor is removed by vacuum, and then carbon monoxide is introduced to make the pressure in the reactor reach a certain value, and then slowly heated to a certain temperature ° C, keeping the pressure in the reactor unchanged. After the reaction is completed, the reaction liquid is filtered, and water is added to the reaction system while hot, and then dichloromethane is added. After stirring, the reaction liquid is filtered, and the filtrate is separated into an organic phase, and the aqueous phase is extracted with dichloromethane for multiple times. The organic phases are combined, concentrated, and separated and purified by silica gel column chromatography to obtain 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione.
[0010] 3. Add a certain amount of 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindole-1,3-dione, copper powder and potassium nitrite to N,N-dimethylformamide, stir at room temperature for a period of time under nitrogen protection, then add 50 mL of N,N-dimethylformamide dissolved with N,N-dimethylethylenediamine, zinc iodide and cuprous iodide, maintain nitrogen protection atmosphere, slowly heat to a certain temperature, pour the reaction solution into water after the reaction is complete, filter the reaction solution, and then extract with dichloromethane for several times, combine the organic phases, concentrate and separate by silica gel column chromatography to obtain 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione.
[0011] 4. In a high-pressure reactor, add a certain amount of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione and palladium acetate to a mixed solution of N,N-dimethylformamide, ethanol, tetrahydrofuran and acetone, stir, introduce hydrogen into the reactor, replace the gas in the reaction system three times, then make the hydrogen pressure in the reactor reach a certain value, heat to 50°C, stir to react until the raw materials react completely, then pour the reaction solution into water, filter the reaction solution, and then extract with dichloromethane for several times, combine the organic phases, concentrate and separate by silica gel column chromatography to obtain 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione.
[0012] 5. Add a certain amount of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)eth-1-amine to N,N-dimethylformamide, stir to dissolve, then add N,N-diisopropylethylamine, and stir to react at room temperature until the raw material 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione reacts completely. Stir the reaction solution and pour it into water and continue stirring for a while. Then, extract the reaction system with dichloromethane for several times, combine the organic phases, dry over anhydrous sodium sulfate, concentrate in vacuo, and separate by silica gel column chromatography to obtain the azide intermediate compound.
[0013] 6. Add a certain amount of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethan-1-aldehyde and acetic acid to N,N-dimethylformamide, stir and dissolve, then add 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione, stir at room temperature for a period of time, cool the reaction system to 0°C, slowly add sodium triacetoxyborohydride or sodium borohydride dissolved in N,N-dimethylformamide, and heat to room temperature after the addition is complete. Monitor the reaction of the raw materials by TLC, then pour the reaction solution into water, and then extract with dichloromethane for several times. Combine the organic phases, concentrate, add ethanol to dissolve, heat to reflux under nitrogen protection, react for a period of time, cool to 0°C, solid precipitates, filter and dry to obtain an azide intermediate compound.
[0014] 7. Add a certain amount of an azide intermediate compound and 4-aminophenylacetylene or 3-aminophenylacetylene to a mixed solvent of distilled water, tetrahydrofuran and tert-butanol, then add cuprous iodide, protect with nitrogen, heat to 80°C, reflux for a period of time, extract with dichloromethane, combine the organic phases, add a phenyl isocyanate compound, stir the reaction for a period of time, filter with diatomaceous earth, concentrate the filtrate in vacuo, and separate by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) to obtain the target compound.
[0015] The technical advantages of the present invention are as follows: the present invention connects pomalidomide and urea compounds through a long ether chain, the urea structure can be used as an IDO1 inhibitor, pomalidomide can be used as a ligand of E3 ubiquitinase, the obtained small molecule can degrade IDO1 enzyme activity and has an inhibitory effect on urease, and a simple and efficient method for generating nitrobenzene from iodobenzene is developed, and a method for condensing and connecting aldehyde groups with aniline is developed, which is suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 This is the H NMR spectrum of the target compound prepared in Example 1.
[0017] Figure 2This is the H NMR spectrum of the target compound prepared in Example 12.
[0018] Figure 3 This is the H NMR spectrum of the target compound prepared in Example 13.
[0019] Figure 4 This is the H NMR spectrum of the target compound prepared in Example 18. DETAILED DESCRIPTION
[0020] The above contents of the present invention are further described in detail below through examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples, and all technologies implemented based on the above contents of the present invention belong to the scope of the present invention.
[0021] Example 1
[0022]
[0023] In a reaction flask with a stirring device, add 1.4 g of methyl benzoate and 3 g of calcium carbonate to 100 mL of dichloroethane solution, stir, and then slowly drop 100 mL of dichloroethane solution containing 4 g of iodine chloride. After the addition is complete, heat to reflux and stir for 1.5 h, then cool and filter the reaction solution, add 10 g of anhydrous magnesium sulfate, stir for 20 min, filter, add 1.7 g of 3-aminopiperidine-2,6-dione hydrochloride, 1 g of triethylamine, and 2 g of N,N'-dicyclohexylcarboximide to the filtrate, stir and react at room temperature for 15 h, concentrate, wash the concentrate with 50 mL of ether several times, and then add the concentrate to 100 mL of toluene. , then add 2.6 g of triphenylphosphine and 3 g of iodine, heat to reflux, remove water from the reaction system through a water separator, then add 0.23 g of palladium acetate and 1 g of triethylamine, stir for 30 min under nitrogen protection, then add 1.5 g of anhydrous formic acid, maintain a nitrogen atmosphere, adjust the temperature of the reaction system to 80°C, react for 5 h, stop the reaction, filter the reaction solution while hot, add 100 mL of water to the filtrate, stir and extract with 50 mL of dichloromethane for several times, combine the organic phases, concentrate in vacuo, wash with petroleum ether and dry to obtain 3.59 g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione; 1 H NMR (400MHz, DMSO-d6) δ11.12(s,1H),8.24(d,J=4.0Hz,1H),7.90(d,J=8.0Hz,1H),7.54(t,J1=8.0Hz,J2 =4.0Hz, 1H), 5.13 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 2.89-2.81 (m, 1H), 2.59-2.47 (m, 2H), 2.06-2.00 (m, 1H).
[0024] Example 2
[0025]
[0026] In a reaction flask with a stirring device, 1.4 g of methyl benzoate and 3 g of calcium carbonate were added to 100 mL of dichloroethane solution, and then 100 mL of dichloroethane solution containing 4 g of iodine chloride was slowly added dropwise after stirring. After the addition was complete, the mixture was heated to reflux and stirred for 1.5 h, and then the reaction solution was cooled and filtered. 10 g of anhydrous magnesium sulfate was added, and the mixture was stirred for 20 min and filtered. 1.7 g of 3-aminopiperidine-2,6-dione hydrochloride, 1 g of triethylamine and 2 g of N,N'-dicyclohexylcarboximide were added to the filtrate, and the reaction was stirred at room temperature for 15 h. After concentration, the concentrate was washed several times with 50 mL of ether, and then the concentrate was added to 150 mL of glycerol, placed in a high-pressure reactor, and triphenylphosphine chloride was added. 0.28g of palladium, 0.65g of molybdenum acetylacetonate and 1.8g of N,N-dimethylethanolamine were added, stirred evenly, and the air in the reactor was removed by vacuum, and then carbon monoxide was introduced to make the pressure in the reactor reach 1.5MPa, and slowly heated to 120°C, keeping the pressure in the reactor unchanged, reacting for 5h, stopping the reaction, filtering the reaction liquid, adding 100mL of water to the reaction system while hot, and then adding 50mL of dichloromethane, stirring and filtering the reaction liquid, separating the organic phase from the filtrate, extracting the aqueous phase with 50mL of dichloromethane for several times, combining the organic phases, concentrating and separating and purifying by silica gel column chromatography to obtain 3.11g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione; 1 H NMR (400MHz, DMSO-d6) δ11.12(s,1H),8.24(d,J=4.0Hz,1H),7.90(d,J=8.0Hz,1H),7.54(t,J1=8.0Hz,J2 =4.0Hz, 1H), 5.13 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 2.89-2.81 (m, 1H), 2.59-2.47 (m, 2H), 2.06-2.00 (m, 1H).
[0027] Example 3
[0028]
[0029] In a reaction flask with a stirring device, 1.4 g of methyl benzoate and 3 g of calcium carbonate were added to 100 mL of dichloroethane solution, and then 100 mL of dichloroethane solution containing 4 g of iodine chloride was slowly added dropwise after stirring. After the addition was complete, the mixture was heated to reflux and stirred for 1.5 h, and then the reaction solution was cooled and filtered. 10 g of anhydrous magnesium sulfate was added, and the mixture was stirred for 20 min and filtered. 1.7 g of 3-aminopiperidine-2,6-dione hydrochloride, 1 g of triethylamine and 2 g of N,N'-dicyclohexylcarboximide were added to the filtrate, and the reaction was stirred at room temperature for 15 h. After concentration, the concentrate was washed several times with 50 mL of ether, and then added to 150 mL of glycerol, placed in a high-pressure reactor, and triphenylmethane was added. 0.28g of phosphine palladium chloride, 0.6g of molybdenum acetylacetonate and 1.7g of potassium tert-butoxide were stirred evenly and then the air in the reactor was removed by vacuum, and then carbon monoxide was introduced to make the pressure in the reactor reach 1.5MPa, and then slowly heated to 95°C, keeping the pressure in the reactor unchanged, reacting for 12h, stopping the reaction, filtering the reaction liquid, adding 100mL of water to the reaction system while hot, and then adding 50mL of dichloromethane, stirring and filtering the reaction liquid, separating the organic phase from the filtrate, extracting the aqueous phase with 50mL of dichloromethane for several times, combining the organic phases, concentrating and separating and purifying by silica gel column chromatography to obtain 3.65g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione; 1 H NMR (400MHz, DMSO-d6) δ11.12(s,1H),8.24(d,J=4.0Hz,1H),7.90(d,J=8.0Hz,1H),7.54(t,J1=8.0Hz,J2 =4.0Hz, 1H), 5.13 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 2.89-2.81 (m, 1H), 2.59-2.47 (m, 2H), 2.06-2.00 (m, 1H).
[0030] Example 4
[0031]
[0032] In a reaction bottle with a stirring device, 3.9 g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione, 0.19 g of copper powder and 1.7 g of potassium nitrite were added to 150 mL of N,N-dimethylformamide, and stirred at room temperature for 1 h under nitrogen protection. Then, 50 mL of N,N-dimethylformamide containing 1.8 g of N,N-dimethylethylenediamine, 0.32 g of zinc iodide and 0.19 g of cuprous iodide was added. The nitrogen protection atmosphere was maintained, and the temperature was slowly raised to 120°C. After reacting for 6.5 h, the reaction solution was filtered. The filtrate was placed at 0°C, and 50 mL of ethanol solution containing 0.7 g of nitrosamine was added under nitrogen protection in accordance with the laboratory hazardous chemicals use rules. During the dropwise addition, nitrogen and low temperature were maintained. After the dropwise addition, the mixture was stirred for 30 minutes to further convert the unreacted reactants. The reaction solution was then poured into 200 mL of water, stirred and filtered, and then extracted several times with 100 mL of dichloromethane. The organic phases were combined, concentrated, and separated by silica gel column chromatography to obtain 2.14 g of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione. 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),8.32(d,J=8.0Hz,1H),8.20(d,J=4.0Hz,1H),8.08(t,J1=8.0Hz,J2 =4.0Hz,1H),5.16(dd,J1=4.0Hz,J2=4.0Hz,1H),2.89-2.81(m,1H),2.60-2.48(m,2H),2.06-2.01(m,1H).
[0033] Example 5
[0034]
[0035] In a reaction bottle with a stirring device, 3.9 g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione, 0.38 g of copper powder and 1.7 g of potassium nitrite were added to 150 mL of N,N-dimethylformamide, and stirred at room temperature for 1 h under nitrogen protection. Then, 50 mL of N,N-dimethylformamide containing 2.7 g of N,N-dimethylethylenediamine, 0.32 g of zinc iodide and 0.19 g of cuprous iodide was added. The nitrogen protection atmosphere was maintained and the temperature was slowly raised to 120 ℃, after reacting for 4 hours, the reaction liquid was filtered, the filtrate was placed at 0℃, and 50mL of ethanol solution containing 0.7g of nitrosamine was added under nitrogen protection. During the dropwise addition, attention was paid to maintaining nitrogen and low temperature. After the dropwise addition, it was stirred for 30 minutes, and then the reaction liquid was poured into 200mL of water, stirred and filtered, and then extracted with 100mL of dichloromethane for several times. The organic phases were combined, concentrated, and separated by silica gel column chromatography to obtain 2.76g of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione. 1 H NMR (400MHz, DMSO-d6) δ11.15(s,1H),8.32(d,J=8.0Hz,1H),8.20(d,J=4.0Hz,1H),8.08(t,J1=8.0Hz,J2 =4.0Hz,1H),5.16(dd,J1=4.0Hz,J2=4.0Hz,1H),2.89-2.81(m,1H),2.60-2.48(m,2H),2.06-2.01(m,1H).
[0036] Example 6
[0037]
[0038] In a high-pressure reactor, 3 g of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione and 0.23 g of palladium acetate were added to a mixed solution of 5 mL of N,N-dimethylformamide, 10 mL of ethanol, 50 mL of tetrahydrofuran and 50 mL of acetone. After stirring, hydrogen was introduced into the reactor to replace the gas in the reaction system three times, and then the hydrogen pressure in the reactor reached 0.5 MPa. The reaction was heated to 50°C and stirred for 20 hours. The reaction was monitored by TLC to ensure that the raw material reaction was complete. The reaction solution was then poured into 100 mL of water, filtered, and then extracted with 50 mL of dichloromethane for several times. The organic phases were combined, concentrated, and separated by silica gel column chromatography to obtain 2.47 g of 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione.
[0039] Example 7
[0040]
[0041] In a reaction bottle with a stirring device, 3.9 g of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione and 2.2 g of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)eth-1-amine were added to 100 mL of N,N-dimethylformamide, stirred to dissolve, and then 2.5 g of N,N-diisopropylethylamine was added. The mixture was stirred at room temperature for 40 min. After the reaction of the raw material 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione was completed under TLC monitoring, the reaction solution was stirred and poured into water and continued to stir for a period of time, then the reaction system was extracted with dichloromethane for several times, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo, and separated by silica gel column chromatography to obtain 4.36 g of the azide intermediate compound.
[0042] Example 8
[0043]
[0044] In a reaction bottle with a stirring device, 2.2 g of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethyl-1-aldehyde and 10 mL of acetic acid were added to 100 mL of N,N-dimethylformamide, stirred and dissolved, and then 2.8 g of 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione was added, and stirred at room temperature for 30 min. The reaction system was then cooled to 0°C, and 100 mL of N,N-dimethylformamide containing 3.1 g of sodium triacetoxyborohydride was slowly added dropwise. After the addition was complete, the temperature was raised to room temperature. TLC monitored the complete reaction of the raw materials, and then the reaction solution was poured into 200 mL of water, and then extracted with 80 mL of dichloromethane for several times. The organic phases were combined, concentrated, and ethanol was added to dissolve. The mixture was heated to reflux under nitrogen protection, reacted for 2 h, and then cooled to 0°C. Solids precipitated and were filtered and dried to obtain 4.49 g of an azide intermediate compound.
[0045] Example 9
[0046]
[0047] In a reaction bottle with a stirring device, 2.2 g of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethyl-1-aldehyde and 10 mL of acetic acid were added to 100 mL of N,N-dimethylformamide, stirred and dissolved, and then 2.8 g of 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione was added, and stirred at room temperature for 30 min. The reaction system was then cooled to 0°C, and 70 mL of N,N-dimethylformamide containing 1.1 g of sodium borohydride was slowly added dropwise. After the addition was complete, the temperature was raised to room temperature. TLC monitored the complete reaction of the raw materials, and then the reaction solution was poured into 200 mL of water, and then extracted with 80 mL of dichloromethane for several times. The organic phases were combined, concentrated, and ethanol was added to completely dissolve the mixture. The mixture was heated to reflux under nitrogen protection, reacted for 2 h, and then cooled to 0°C. Solids precipitated and were filtered and dried to obtain 4.16 g of an azide intermediate compound.
[0048] Example 10
[0049]
[0050] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 4-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. The mixture was protected by nitrogen and heated to 80°C. The reaction was refluxed for 6 h. The reaction of the raw materials was completed by TLC monitoring. The reaction was stopped, and the organic phases were extracted 4 times with 50 mL of dichloromethane. Then, 2.1 g of 4-trifluoromethylphenyl isocyanate was added. After stirring for a period of time, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 5.89 g of the target compound. 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),9.86-9.70(m,1H),8.42(s,1H),7.76(d,J=4.0Hz,2H),7.69(d,J=4 .0Hz,2H),7.64(d,J=4.0Hz,2H),7.58-7.54(m,3H),7.11(d,J=4.0Hz,1H),7.03(d,J=8.0Hz,1H),6.57(t, J1=4.0Hz, J2=4.0Hz, 1H), 5.07-5.04(m, 1H), 4.54(t, J1=4.0Hz, J2=4.0Hz, 2H), 3.85(t, J1=4.0Hz, J2=4. 0Hz,2H),3.58–3.50(m,12H),2.90-2.85(m,1H),2.63-2.57(m,1H),2.04–1.98(m,1H),1.88-1.80(m,1H).
[0051] Embodiment 11
[0052]
[0053] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 3-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 9 h. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped, and the mixture was extracted with 50 mL of dichloromethane 4 times. The organic phases were combined, and 1.65 g of 4-methoxyphenylisocyanate was added. After stirring for a period of time, the mixture was filtered with diatomaceous earth, and the filtrate was concentrated in vacuo. The target compound 2.82 g was separated by silica gel column chromatography using dichloromethane and methanol (V / V=15:1) as eluents. 1 H NMR (400MHz, DMSO) δ10.99 (s, 1H), 8.58 (s, 1H), 8.35 (d, J = 8.0Hz, 1H), 7.42 (t, J1 = 4.0Hz, J2 = 8.0Hz, 1H),7.27-7.18(m,5H),6.96–6.89(m,2H),6.75(d,J=12.0Hz,2H),6.46–6.42(m,1H),5.62(s,1H),4 .94(dd,J1=8.0Hz,J2=4.0Hz,1H),4.45–4.40(m,2H),3.74(t,J1=4.0Hz,J2=4.0Hz,2H),3.60(s,3H) ,3.45-3.41(m,7H),3.29-3.26(m,4H),2.82-2.72(m,1H),2.46-2.38(m,2H),1.91(d,J=8.0Hz,1H).
[0054] Example 12
[0055]
[0056] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 3-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 7 hours. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped, and the organic phases were extracted four times with 50 mL of dichloromethane. Then, 2.2 g of phenyl 4-bromoisocyanate was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain the target compound.1 H NMR (400MHz, DMSO) δ11.14(s,1H),8.86(s,2H),8.50(s,1H),8.07(s,1H),7.57(t,J1=8. 0Hz, J2=8.0Hz,1H),7.49–7.45(m,5H),7.42-7.35(m,2H),7.11-7.05(m,2H),6.59(s,1H) ),5.09(dd,J1=4.0Hz,J2=4.0Hz,1H),4.59(s,2H),3.89(t,J1=4.0Hz,J2=4.0Hz,2H),3. 60–3.53(m,10H),3.44(s,2H),2.96-2.87(m,1H),2.62–2.52(m,2H),2.07–2.02(m,1H).
[0057] Example 13
[0058]
[0059] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 3-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 5 h. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped and extracted four times with 50 mL of dichloromethane. The organic phases were combined and 1.7 g of phenyl 4-chloroisocyanate was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 3.71 g of the target compound.
[0060] Embodiment 14
[0061]
[0062] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 3-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 12 h. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped and extracted four times with 50 mL of dichloromethane. The organic phases were combined and 2.1 g of 4-trifluoromethylphenyl isocyanate was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 5.16 g of the target compound.
[0063] Embodiment 15
[0064]
[0065] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 3-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 8 hours. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped and extracted four times with 50 mL of dichloromethane. The organic phases were combined and 1.55 g of phenyl 4-fluoroisocyanate was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 4.14 g of the target compound.
[0066] Example 16
[0067]
[0068] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 4-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 4 hours. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped and extracted four times with 50 mL of dichloromethane. The organic phases were combined and 1.55 g of phenyl 4-fluoroisocyanate was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 5.33 g of the target compound.
[0069] Embodiment 17
[0070]
[0071] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 4-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 5 h. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped and extracted four times with 50 mL of dichloromethane. The organic phases were combined and 1.6 g of 4-nitriloisocyanatophenyl ester was added. After stirring the reaction for a while, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography with dichloromethane and methanol (V / V=15:1) as eluents to obtain 4.72 g of the target compound.
[0072] Embodiment 18
[0073]
[0074] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 4-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. The mixture was protected by nitrogen and heated to 80°C. The reaction was refluxed for 5 h. The reaction of the raw materials was completed by TLC monitoring. The reaction was stopped, and the organic phases were extracted 4 times with 50 mL of dichloromethane. Then, 2.2 g of phenyl bromoisocyanate was added. After stirring for a period of time, the mixture was filtered with diatomaceous earth. The filtrate was concentrated in vacuo and separated by silica gel column chromatography using dichloromethane and methanol (V / V=15:1) as eluents to obtain 3.96 g of the target compound. 1 H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.84(s,1H),8.81(s,1H),8.41(s1H),7.75(d,J=8.0Hz,2H),7 .57-7.52(m,3H),7.47-7.43(m,5H),7.11(d,J=4.0Hz,1H),7.04(d,J=4.0Hz,1H),6.58(t,J1=4.0Hz ,J2=4.0Hz,1H),5.07-5.04(m,1H),4.54(t,J1=4.0Hz,J2=4.0Hz,2H),3.85(t,J1=4.0Hz,J2=4.0Hz, 2H),3.58–3.51(m,10H),3.43-3.41(m,2H),2.91–2.85(m,1H),2.60-2.55(m,1H),2.04–2.01(m,1H).
[0075] Embodiment 19
[0076]
[0077] In a reaction bottle with a stirring device, 4.8 g of the azide intermediate compound and 1.4 g of 4-aminophenylacetylene were added to 200 mL of a mixed solvent of distilled water, tetrahydrofuran and tert-butanol (the volume ratio of the three was 1:1:1), and then 0.19 g of cuprous iodide was added. Under nitrogen protection, the mixture was heated to 80°C and refluxed for 7 h. The reaction of the raw materials was completed after TLC monitoring. The reaction was stopped, and the mixture was extracted with 50 mL of dichloromethane 4 times. The organic phases were combined, and 1.7 g of phenyl 4-chloroisocyanate was added. After stirring for a period of time, the mixture was filtered with diatomaceous earth, and the filtrate was concentrated in vacuo. The target compound 5.57 g was separated by silica gel column chromatography using dichloromethane and methanol (V / V=15:1) as eluents. 1H NMR (400MHz, DMSO-d6) δ11.10(s,1H),8.83(s,1H),8.80(s,1H),8.41(s1H),7.75(d,J=8.0Hz,2H),7.57- 7.49(m,5H),7.34(d,J=4.0Hz,2H),7.11(d,J=4.0Hz,1H),7.03(d,J=8.0Hz,1H),6.57(t,J1=4.0Hz,J2=4. 0Hz,1H),5.07-5.04(m,1H),4.54(t,J1=4.0Hz,J2=4.0Hz,2H),3.85(t,J1=4.0Hz,J2=4.0Hz,2H),3.58–3 .50(m,10H),3.42(dd,J1=4.0Hz,J2=4.0Hz,2H),2.91–2.85(m,1H),2.60-2.57(m,1H),2.03–2.01(m,1H).
[0078] Embodiment 20
[0079] After cell recovery, HeLa cells were plated at 5 x 10 4 The cells were seeded into a 96-well culture plate at a density of 1.50 μg / mL. DMEM culture medium was added to the wells. The 96-well plate was placed in a 5% CO 2 37 ℃ incubator overnight. After 24 hours, human IFN-γ (diluted with culture medium) and test compound solution (diluted with culture medium to different concentrations of 0.1, 1, 10, 0.3, 3, 30 μM) were added to each well, 20 μL per well. The 96-well plate was placed in a 37 ℃ incubator with 5% CO2 and cultured overnight. After 48 hours, 140 μL of supernatant was taken out from each well and transferred to a new 96-well plate. 20 μL of 6.1N trichloroacetic acid was added to each well, mixed and cultured at 50 ℃ for 30 minutes. The reaction mixture was then centrifuged at 2500 rpm for 10 minutes, and 100 μL of supernatant per well was transferred to another 96-well plate and mixed with 100 μL of 2% (w / v) p-dimethylaminobenzaldehyde acetic acid solution. The content of the yellow product derived from L-kynurenine was measured at 480 nm using an ELISA reader. Each drug was tested three times using the same batch of cells at different passages, and the compound IC was calculated using Graphpad Prism 5.0 using nonlinear regression. 50 The IC values of Examples 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19 are 50 The values were >100, >100, 3.5, 30.82, >100, >100, >100, >100, 50.2, and >100 μM, respectively.
[0080] Embodiment 21
[0081] We selected the compounds obtained in Examples 12, 13 and 18 with the best IDO1 activity for in vitro urease inhibition experiments: yellow cattle of about 12 months old were selected, and after feeding for 1 hour, 400 mL of rumen fluid was collected through an artificial rumen fistula using a special rumen fluid collector, filtered through 4 layers of gauze and set aside. After adding the corresponding reagents to each culture tube according to the amount in the table below, 4 drops of liquid paraffin were added, and the tube was gently shaken on a (39.0±0.5)°C constant temperature water bath oscillator. After culturing for 8 hours, some culture tubes were taken out from each group, and 4 drops of saturated mercuric chloride solution were immediately added and shaken to terminate the reaction. The ammonia nitrogen content of each tube was determined by the Kjeldahl semi-micro-saturated magnesium oxide distillation method. We can find that the compound obtained in the designed Example 12 has an increasingly significant inhibitory activity on urease with the extension of time, and has a very significant inhibitory effect; and through the CCK8 experiment, it has low toxicity to the human renal epithelial cell line 293T cells, IC 50 Values >100 μM.
[0082] Group Control group Test Group 1 Test Group 2 Rumen fluid / mL 5 5 5 Artificial saliva / mL 5 5 5 Soluble starch / mg 6 6 6 Urea nitrogen / mg 5 5 5 Example 12 Product / mg 0 4 8 Example 13 Product / mg 0 4 8 Example 18 Product / mg 0 4 8
[0083] Inhibition rate (%) = (ammonia content of control group - ammonia content of test group) ÷ ammonia content of control group × 100%
[0084] serial number Time (h) The inhibition rate of the control group Inhibition rate of test group 1 Inhibition rate of test group 2 Example 12 Product 8 0% 42.77% 61.53% Example 13 Product 8 0% 28.64% 39.76% Example 18 Product 8 0% 20.49% 27.25%
[0085] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of protection of the present invention.
Claims
1. A pomalidomide derivative that can be used as a feed additive, characterized in that: The molecular structure of the pomalidomide derivative is: wherein R is a methoxy, bromine, chlorine or fluorine atom.
2. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 1, characterized in that: The specific preparation process is as follows: a certain amount of an azide intermediate compound and 4-aminophenylacetylene or 3-aminophenylacetylene are added to a mixed solvent of distilled water, tetrahydrofuran and tert-butyl alcohol, and then cuprous iodide is added, nitrogen protection is applied, the mixture is heated to 80°C, refluxed for a period of time, extracted with dichloromethane, the organic phases are combined, and then phenyl isocyanate compounds are added. After stirring for a period of time, the mixture is filtered with diatomaceous earth, the filtrate is vacuum concentrated, and the pomalidomide derivative is separated by silica gel column chromatography using dichloromethane and methanol as eluents; the molar ratio of the azide intermediate compound to 4-aminophenylacetylene or 3-aminophenylacetylene and cuprous iodide is 1:1:0.2; the molar ratio of the azide intermediate compound to phenyl isocyanate compounds is 1:1-1.1; the azide intermediate is The phenyl isocyanate compound is 4-methoxyphenyl isocyanate, 4-bromophenyl isocyanate, 4-chlorophenyl isocyanate or 4-fluorophenyl isocyanate.
3. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 2, characterized in that: The specific process for preparing the azide intermediate is as follows: a certain amount of 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)eth-1-amine are added to N,N-dimethylformamide, stirred to dissolve, and then N,N-diisopropylethylamine is added, and stirred at room temperature to react until the raw material 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione is completely reacted. The reaction mixture is stirred and poured into water and stirred for a period of time, then the reaction system is extracted with dichloromethane for multiple times, the organic phases are combined, dried over anhydrous sodium sulfate, concentrated in vacuo, and separated by silica gel column chromatography to obtain an azide intermediate compound; the molar ratio of the 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione to 2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethane-1-amine to N,N-diisopropylethylamine is 1:1:
2.
4. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 2, characterized in that: The specific process for preparing the azide intermediate is as follows: a certain amount of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethane-1-aldehyde and acetic acid are added to N,N-dimethylformamide, stirred and dissolved, and then 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione is added. After stirring at room temperature for a period of time, the reaction system is cooled to 0°C, and a N,N-dimethylformamide solution containing sodium triacetoxyborohydride or sodium borohydride is slowly added dropwise. After the addition is completed, the temperature is raised to room temperature, and the reaction of the raw material is monitored by TLC. The reaction mixture should be complete, and then the reaction solution is poured into water, and then extracted with dichloromethane for several times, the organic phases are combined, concentrated, and ethanol is added to dissolve, and the mixture is heated to reflux under nitrogen protection, reacted for 2 hours, cooled to 0°C, solid precipitated, filtered and dried to obtain an azide intermediate compound; the molar ratio of the feeding amount of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)ethan-1-aldehyde and 2-(2,6-dioxopiperidine-3-yl)-4-aminoisoindoline-1,3-dione to sodium triacetoxyborohydride or sodium borohydride is 1:1:1.2~3.
5. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 4, characterized in that: The specific preparation process of the 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione is as follows: in a high-pressure reactor, a certain amount of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione and palladium acetate are added to a mixed solution of N,N-dimethylformamide, ethanol, tetrahydrofuran and acetone, and hydrogen is introduced into the reactor after stirring to replace the gas in the reaction system three times, and then the hydrogen pressure of the reactor reaches a certain value, and the reactor is heated to 50 ℃, stirring to react until the raw materials react completely, then pouring the reaction solution into water, filtering the reaction solution, and then extracting with dichloromethane for multiple times, combining the organic phases, concentrating and separating by silica gel column chromatography to obtain 2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline-1,3-dione; the molar ratio of the feeding amount of 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione and palladium acetate is 1:0.1; the hydrogen pressure of the reactor is 0.3-0.5MPa.
6. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 5, characterized in that: The specific preparation process of the 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione is as follows: a certain amount of 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindole-1,3-dione, copper powder and potassium nitrite are added to N,N-dimethylformamide, stirred at room temperature for a period of time under nitrogen protection, and then N,N-dimethylformamide solution containing N,N-dimethylethylenediamine, zinc iodide and cuprous iodide is added, the nitrogen protection atmosphere is maintained, the temperature is slowly raised to a certain temperature, and the reaction is performed for a period of time. The filtrate is placed at 0°C, and an ethanol solution containing nitrosamine is added under nitrogen protection. During the dropwise addition, the nitrogen and the reaction solution are kept at 0°C. After the dropwise addition is completed, the temperature is stirred and reacted. The reaction solution is poured into water, the reaction solution is filtered, and then extracted with dichloromethane for multiple times. The organic phases are combined, concentrated, and separated by silica gel column chromatography to obtain 2-(2,6-dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione; the molar ratio of the feeding amount of the 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindole-1,3-dione to copper powder and potassium nitrite is 1:0.3-0.6:1.5-2; the molar ratio of the feeding amount of the 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindole-1,3-dione to N,N-dimethylethylenediamine to zinc iodide and cuprous iodide is 1:2-3:0.1:0.1; the certain temperature is 100-120°C.
7. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 6, characterized in that: The specific preparation process of the 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione is as follows: a certain amount of methyl benzoate and calcium carbonate are added to a dichloroethane solution, and then a certain amount of iodine chloride dissolved in a dichloroethane solution is slowly added dropwise after stirring, and after the addition is complete, the dichloroethane solution is heated to reflux and stirred for a period of time, and then the reaction liquid is cooled and filtered, and then anhydrous magnesium sulfate is added, stirred and filtered, and a certain amount of 3-aminopiperidine-2,6-dione hydrochloride, triethylamine and N,N'-dicyclohexylcarboximide are added to the filtrate, and the reaction is stirred for a period of time at room temperature and then concentrated, and then the concentrate is washed with ether for multiple times, and then the concentrate is added to glycerol, placed in a high-pressure reactor, and then a certain amount of triphenylphosphine palladium chloride and acetylacetonate molybdenum and alkaline substances are added, and after stirring evenly, the air in the reactor is removed by vacuum, and then an oxide is introduced. Carbon, make the pressure in the reactor reach a certain value, slowly heat to a certain temperature, keep the pressure in the reactor unchanged, filter the reaction liquid after the reaction is completed, add water to the reaction system while hot, then add dichloromethane, stir and filter the reaction liquid, separate the filtrate into an organic phase, extract the aqueous phase with dichloromethane for multiple times, combine the organic phases, concentrate and separate and purify by silica gel column chromatography to obtain 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione; the mass ratio of the feeding amount of methyl benzoate to triphenylphosphine palladium chloride is 1:0.2; the molar ratio of the feeding amount of methyl benzoate to molybdenum acetylacetonate and the alkaline substance is 1:0.2:1-2; the alkaline substance is N,N-dimethylethanolamine or potassium tert-butoxide; the pressure in the reactor is 1-1.5MPa; the certain temperature is 100-120℃.
8. The method for preparing a pomalidomide derivative that can be used as a feed additive according to claim 6, characterized in that: The specific process for preparing the 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione is as follows: a certain amount of methyl benzoate and calcium carbonate are added to a dichloroethane solution, and then a dichloroethane solution containing iodine chloride is slowly added dropwise after stirring, and after the addition is completed, the reaction solution is heated to reflux and stirred for a period of time, and then cooled and filtered, and then anhydrous magnesium sulfate is added, stirred and filtered, and a certain amount of 3-aminopiperidine-2,6-dione hydrochloride, triethylamine and N,N'-dicyclohexylcarboximide are added to the filtrate, and the reaction is stirred for a period of time at room temperature, and then concentrated, and then the concentrate is washed with ether for multiple times, and then the concentrate is added to toluene, and then triphenylphosphine and iodine are added, and the mixture is heated to reflux, and the water in the reaction system is removed through a water separator, and then a certain amount of palladium acetate and triethylamine are added, and the mixture is stirred for a period of time under nitrogen protection, and then anhydrous water formic acid, maintain nitrogen atmosphere, adjust the temperature of the reaction system to 80°C, stop the reaction after the reaction is completed, filter the reaction solution while hot, add water, stir and extract with dichloromethane for several times, combine the organic phases, and concentrate to obtain 2-(2,6-dioxo-piperidin-3-yl)-4-iodo-isoindole-1,3-dione; the molar ratio of the feeding amount of methyl benzoate to calcium carbonate and iodine chloride is 1:2.5-3:2-2.5; the molar ratio of the feeding amount of methyl benzoate to 3-aminopiperidine-2,6-dione hydrochloride to triethylamine and N,N'-dicyclohexylcarboximide is 1:1:1:2; the molar ratio of the feeding amount of methyl benzoate to triphenylphosphine to iodine element to palladium acetate and triethylamine added for the second time is 1:1.2:1.2:0.1:1; the molar ratio of the feeding amount of methyl benzoate to anhydrous formic acid is 1:
3.
9. Use of the pomalidomide derivative according to claim 1 in the preparation of a drug for inhibiting IDO1 enzyme activity or urease activity.
Citation Information
Patent Citations
Imide-based modulators of proteolysis and associated methods of use
CN108136044A
Pyridazine triazole drug molecule with sterilization and disinfection effect and preparation method and application thereof
CN110204548A
Triazole feed additive as well as preparation method and application thereof
CN114591252A
Urea feed additive as well as preparation method and application thereof
CN114591253A
